Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Summary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimer...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Cell Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124724000998 |
| _version_ | 1797291791686303744 |
|---|---|
| author | Jiaqi Liang Guoshu Bi Qihai Sui Guangyin Zhao Huan Zhang Yunyi Bian Zhencong Chen Yiwei Huang Junjie Xi Yu Shi Qun Wang Cheng Zhan |
| author_facet | Jiaqi Liang Guoshu Bi Qihai Sui Guangyin Zhao Huan Zhang Yunyi Bian Zhencong Chen Yiwei Huang Junjie Xi Yu Shi Qun Wang Cheng Zhan |
| author_sort | Jiaqi Liang |
| collection | DOAJ |
| description | Summary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimertinib-resistant or drug-tolerant persister LUAD cells and clinical residual tumors. ZNF263 overexpression improves the initial response of cells and delays the formation of persister cells with osimertinib treatment. We further show that ZNF263 binds and recruits DNMT1 to the EGFR gene promoter, suppressing EGFR transcription with DNA hypermethylation. ZNF263 interacts with nuclear EGFR, impairing the EGFR-STAT5 interaction to enhance AURKA expression. Overexpressing ZNF263 also makes tumor cells with wild-type EGFR expression or refractory EGFR mutations more susceptible to EGFR inhibition. More importantly, lentivirus or adeno-associated virus (AAV)-mediated ZNF263 overexpression synergistically suppresses tumor growth and regrowth with osimertinib treatment in xenograft animal models. These findings suggest that enhancing ZNF263 may achieve complete response in LUAD with EGFR-targeted therapies. |
| first_indexed | 2024-03-07T19:42:51Z |
| format | Article |
| id | doaj.art-c2ee8e62c73b4b4c9b876428f4dc025c |
| institution | Directory Open Access Journal |
| issn | 2211-1247 |
| language | English |
| last_indexed | 2024-03-07T19:42:51Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Reports |
| spelling | doaj.art-c2ee8e62c73b4b4c9b876428f4dc025c2024-02-29T05:18:56ZengElsevierCell Reports2211-12472024-02-01432113771Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinomaJiaqi Liang0Guoshu Bi1Qihai Sui2Guangyin Zhao3Huan Zhang4Yunyi Bian5Zhencong Chen6Yiwei Huang7Junjie Xi8Yu Shi9Qun Wang10Cheng Zhan11Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Corresponding authorDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Corresponding authorSummary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimertinib-resistant or drug-tolerant persister LUAD cells and clinical residual tumors. ZNF263 overexpression improves the initial response of cells and delays the formation of persister cells with osimertinib treatment. We further show that ZNF263 binds and recruits DNMT1 to the EGFR gene promoter, suppressing EGFR transcription with DNA hypermethylation. ZNF263 interacts with nuclear EGFR, impairing the EGFR-STAT5 interaction to enhance AURKA expression. Overexpressing ZNF263 also makes tumor cells with wild-type EGFR expression or refractory EGFR mutations more susceptible to EGFR inhibition. More importantly, lentivirus or adeno-associated virus (AAV)-mediated ZNF263 overexpression synergistically suppresses tumor growth and regrowth with osimertinib treatment in xenograft animal models. These findings suggest that enhancing ZNF263 may achieve complete response in LUAD with EGFR-targeted therapies.http://www.sciencedirect.com/science/article/pii/S2211124724000998CP: Cancer |
| spellingShingle | Jiaqi Liang Guoshu Bi Qihai Sui Guangyin Zhao Huan Zhang Yunyi Bian Zhencong Chen Yiwei Huang Junjie Xi Yu Shi Qun Wang Cheng Zhan Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma Cell Reports CP: Cancer |
| title | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| title_full | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| title_fullStr | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| title_full_unstemmed | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| title_short | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| title_sort | transcription factor znf263 enhances egfr targeted therapeutic response and reduces residual disease in lung adenocarcinoma |
| topic | CP: Cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2211124724000998 |
| work_keys_str_mv | AT jiaqiliang transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT guoshubi transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT qihaisui transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT guangyinzhao transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT huanzhang transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT yunyibian transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT zhencongchen transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT yiweihuang transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT junjiexi transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT yushi transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT qunwang transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma AT chengzhan transcriptionfactorznf263enhancesegfrtargetedtherapeuticresponseandreducesresidualdiseaseinlungadenocarcinoma |